

STUDY PROTOCOL

Open Access

# The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine

Jason L Vassy<sup>1,3</sup>, Denise M Lautenbach<sup>3</sup>, Heather M McLaughlin<sup>4,5</sup>, Sek Won Kong<sup>6,7</sup>, Kurt D Christensen<sup>2,3</sup>, Joel Krier<sup>3,7</sup>, Isaac S Kohane<sup>8</sup>, Lindsay Z Feuerman<sup>9</sup>, Jennifer Blumenthal-Barby<sup>9</sup>, J Scott Roberts<sup>10</sup>, Lisa Soleymani Lehmann<sup>11</sup>, Carolyn Y Ho<sup>12</sup>, Peter A Ubel<sup>13</sup>, Calum A MacRae<sup>3,12</sup>, Christine E Seidman<sup>12,14</sup>, Michael F Murray<sup>15</sup>, Amy L McGuire<sup>9</sup>, Heidi L Rehm<sup>4,5</sup>, and Robert C Green<sup>16\*</sup> for the MedSeq Project

## Abstract

**Background:** Whole genome sequencing (WGS) is already being used in certain clinical and research settings, but its impact on patient well-being, health-care utilization, and clinical decision-making remains largely unstudied. It is also unknown how best to communicate sequencing results to physicians and patients to improve health. We describe the design of the MedSeq Project: the first randomized trials of WGS in clinical care.

**Methods/Design:** This pair of randomized controlled trials compares WGS to standard of care in two clinical contexts: (a) disease-specific genomic medicine in a cardiomyopathy clinic and (b) general genomic medicine in primary care. We are recruiting 8 to 12 cardiologists, 8 to 12 primary care physicians, and approximately 200 of their patients. Patient participants in both the cardiology and primary care trials are randomly assigned to receive a family history assessment with or without WGS. Our laboratory delivers a genome report to physician participants that balances the needs to enhance understandability of genomic information and to convey its complexity. We provide an educational curriculum for physician participants and offer them a hotline to genetics professionals for guidance in interpreting and managing their patients' genome reports. Using varied data sources, including surveys, semi-structured interviews, and review of clinical data, we measure the attitudes, behaviors and outcomes of physician and patient participants at multiple time points before and after the disclosure of these results.

**Discussion:** The impact of emerging sequencing technologies on patient care is unclear. We have designed a process of interpreting WGS results and delivering them to physicians in a way that anticipates how we envision genomic medicine will evolve in the near future. That is, our WGS report provides clinically relevant information while communicating the complexity and uncertainty of WGS results to physicians and, through physicians, to their patients. This project will not only illuminate the impact of integrating genomic medicine into the clinical care of patients but also inform the design of future studies.

**Trial registration:** ClinicalTrials.gov identifier NCT01736566

**Keywords:** Whole genome sequencing, Genome report, Genomic medicine, Translational genomics, Primary care, Cardiomyopathy genetics

\* Correspondence: [rcgreen@genetics.med.harvard.edu](mailto:rcgreen@genetics.med.harvard.edu)

<sup>16</sup>Genomes2People and Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute and Harvard Medical School, 41 Avenue Louis Pasteur, Suite 301, 02115 Boston, MA, USA  
Full list of author information is available at the end of the article

## Background

The sequencing of the human genome has brought with it the promise of a genomic revolution for clinical medicine. Many already envision a time when each person's genome will be sequenced and available over the course of the life span as a resource, providing guidance for personalized approaches to health maintenance and disease prevention and treatment. Whole genome sequencing (WGS) is the laboratory process of determining most, if not all, of the 3 billion DNA base pairs across the 46 chromosomes of an individual's genome. The first human genome sequence in the year 2003 cost almost \$3 billion and took more than 10 years to complete [1]. The costs of sequencing have dropped significantly since then, and patients and physicians increasingly have access to WGS services in research and clinical settings [2-10]. At the same time, thousands of new genetic associations with human disease have been identified [11]. WGS can capture much of this information in a single clinical test for an individual, thereby simultaneously delivering genetic results for rare Mendelian diseases, common polygenic diseases, and personalized pharmacogenomics-based medication safety and efficacy.

The potential benefits of WGS seem substantial for a health-care environment that is increasingly emphasizing a more patient-centered, personalized, and preventative approach to wellness. Genetically personalized strategies might counteract the patient and physician frustrations that sometimes stem from the one-size-fits-all paradigm of evidence-based medicine [12]. However, certain factors may obstruct the successful integration of WGS into clinical care. First, laboratories must develop scalable pipelines to sequence genomes, ensure the quality of WGS data, define the validity and utility criteria that variants should meet to be reported to physicians, and appropriately interpret and deliver WGS results to physicians and their patients [9]. Then, patients will look to their health-care providers for guidance on how to interpret and act on WGS information [13]. In the absence of evidence for the clinical validity and utility of WGS in most clinical settings, it is unknown how providers will use WGS results in clinical care. Without adequate physician preparedness, the introduction of such inherently complex and probabilistic risk information to the patient-physician encounter may result in clinical chaos. The application of WGS to large numbers of individuals thus has the potential to uncover unanticipated findings whose impact on clinical care is, at present, impossible to quantify. The resulting confusion, coupled with the instincts of patients and clinicians to order additional medical tests, has the potential to increase health-care costs and iatrogenic harm without increasing value [14,15].

Nevertheless, the application of sequencing to an individual's health care is highly likely in one form or another.

Patients have expressed the desire to integrate genome-wide information into the physician-patient relationship and may even feel that physicians have an obligation to do so [13]. The development of standards and procedures for the use of WGS information in clinical medicine is thus an urgent need [16], and yet there is insufficient evidence and considerable uncertainty in how to do so [17,18]. With this state of the science in mind, we are conducting the MedSeq Project: a feasibility study implementing two randomized trials of WGS in clinical medicine. We have designed a study protocol to enroll both physicians and their patients as study participants, to sequence and interpret patients' genomes, and to deliver clinical genome reports to physicians for use in clinical care. In this study, the questions we seek to answer include the following:

*How should a clinical molecular genetics laboratory process and report WGS results to physicians and their patients in an intelligible way without oversimplifying the inherent complexity and uncertainty of WGS data?*

*With education and appropriate support, will non-geneticist physicians feel adequately prepared to discuss and manage WGS results with their patients?*

*How will the delivery of WGS results, some with unclear clinical significance, impact the actions, attitudes and outcomes of patients and their physicians?*

Below we describe the design of the MedSeq Project protocol. In particular, we discuss the rationale for our study design and describe our protocol for recruiting physicians and patients to the study, randomly assigning patient participants to receive WGS or standard of care, educating physician participants about WGS, and measuring the impact of introducing WGS into clinical medicine.

## Methods/design

### Models of genomic medicine

Genome sequencing will be integrated into clinical care in many ways. It is already demonstrating clinical utility for the diagnosis and treatment of certain cancers [5,19] and rare diseases [2,3,20-22] and shows promise for use in infectious disease outbreaks [23-25] and fetal diagnosis in prenatal medicine [7,26]. The design of the MedSeq Project models two archetypal scenarios for how WGS could be integrated into clinical care. First, in situations in which a patient presents with a particular family history, symptom, or clinical syndrome, the genomic sequence may be specifically interrogated for a genetic cause for that particular presentation, a scenario we call *disease-specific genomic medicine*. In this scenario, analysis of the genome focuses on known or suspected variants in relevant

disease-associated genes. For many genetic conditions, sequencing of candidate genes is already common practice, and the interrogation includes rigorous evaluation of novel variants that may have little or no prior exposure in the scientific literature or in available databases. At the same time, WGS may uncover incidental findings not related to the original indication for sequencing [27,28]. In a very different scenario in which the patient is generally healthy and does not have a family history suggestive of a genetic condition, the genome could be sequenced as a part of routine preventive medicine. We call this scenario *general genomic medicine*. Whereas disease-specific genomic medicine mirrors today's practice in medical genetics of investigating the underlying genetic etiology of a clinical presentation, general genomic medicine is conceptually different from any genetics commonly practiced today. It more closely resembles current population-based preventive screening measures in clinical practice, such as newborn screening for metabolic disorders and adult screening for breast, cervical, and colorectal cancer. Among individuals without a specific indication for WGS, general genomic medicine examines the genomes for disease variants meeting an agreed-upon threshold for clinical relevance. Given the higher risk of false-positive test results in this generally healthy population, general genomic medicine requires higher standards of certainty and clinical significance. It also incorporates well-established pharmacogenomic associations so that clinicians can query a patient's sequence for the likelihood of drug efficacy and safety when a new medication is prescribed. Moreover, carrier status results for recessive Mendelian traits such as Tay-Sachs disease and cystic fibrosis allow patients and their family members to recognize the presence of carrier states and to consider preconception screening or prenatal surveillance.

To model *disease-specific genomic medicine*, we are drawing on the expertise in the diagnosis, management, and molecular etiology of hypertrophic and dilated cardiomyopathy (HCM and DCM) among our study investigators at the Brigham and Women's Hospital Cardiovascular Genetics Center. To answer the question of how WGS might impact the clinical care of HCM and DCM as compared with standard of care, we are enrolling cardiologists and their patients with HCM or DCM who have previously undergone or are preparing to undergo targeted genetic testing for a panel of genes known to be associated with cardiomyopathy. One example of such a standard genetic test is the Partners Laboratory for Molecular Medicine's Pan Cardiomyopathy Panel, a targeted interrogation of 51 genes associated with conditions such as HCM, DCM, arrhythmogenic right ventricular cardiomyopathy, and left ventricular non-compaction [29]. To model *general genomic medicine*, we are recruiting primary care physicians (PCPs) and their generally healthy adult

patients from the network of primary care practices at Brigham and Women's Hospital, a network of more than 100 PCPs at 13 sites in the greater Boston area serving a diverse patient population of almost 100,000. This model of general genomic medicine uses WGS as an adjunct to routine preventive care in a population of patients without a specific indication for genetic testing.

#### Overview of study design


Figure 1 shows the MedSeq Project study schema. A randomized controlled trial design enhances our ability to isolate the effect of WGS disclosure on patient and physician attitudes and behaviors. Within each of the cardiology and primary care trials, we randomly assign patient participants to WGS versus standard of care and then study the impact of disclosing this risk information to physician and patient participants. The Partners Healthcare institutional review board approved this study protocol.

#### Recruitment, enrollment, and sample size

We are recruiting a convenience sample of 8 to 12 PCPs and 8 to 12 cardiologists specializing in cardiomyopathy at our institution via individual and group e-mail communication and informational presentations for individual providers and group practices. Once enrolled in the study, each physician participant identifies and recruits 8 to 12 of his or her eligible patients, using study brochures, letters, phone calls, and in-person conversations. Potential patient participants are referred to study staff, who confirm eligibility and obtain informed consent during an in-person encounter. Our enrollment target is 200 total patient participants: 100 from primary care and 100 from cardiology. The MedSeq Project is a feasibility study that examines many outcomes; this targeted sample size is not formally designed to achieve statistical power for one specific primary outcome. Physician participants are compensated for their time at the end of the study regardless of the number of patients enrolled. Patient participants are compensated at the end of the study after completion of the 6-month survey and must complete all study surveys to receive compensation. A subset of patient participants is invited to complete qualitative interviews and receives additional compensation. Patient and physician incentives are intended to minimize losses to follow-up and occurrences of missing data.

#### Patient inclusion and exclusion criteria

Table 1 shows the inclusion and exclusion criteria of the MedSeq Project patient participants. All patient participants must be receiving care from one of the physician participants, all of whom are affiliated with our institution. Patient participants in the primary care trial are generally healthy adults who are 40 to 65 years old. Patient participants in the cardiology trial have a diagnosis



**Figure 1** MedSeq project study schema. DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy.

**Table 1** Overall inclusion and exclusion criteria of the MedSeq project patient participants, plus additional criteria specific to the primary care or subspecialty cardiology trials

	Both trials	Primary care trial	Cardiology trial
Inclusion criteria	Patients receiving care from MedSeq Project physician participants	Age 40-65 years Generally healthy, in the judgment of the patient's participating physician No indication for a genetic test	Age 18-90 years Diagnosis of hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM) Prior or concurrent targeted genetic testing for HCM or DCM
Exclusion criteria	Clinically significant anxiety (Hospital Anxiety and Depression Scale [HADS] anxiety subscale >14) or depression (HADS depression subscale >16) at baseline assessment Reported current pregnancy or intention for future conception in the next year of participant or spouse/partner	Presence of cardiovascular disease or diabetes	

of HCM or DCM and have prior or concurrent targeted genetic testing for this condition. Any patient with a score of more than 14 or more than 16 on the anxiety and depression subscales, respectively, of the Hospital Anxiety and Depression Scale (HADS) [30] is excluded from enrollment; a study clinician explains the HADS result to the patient and makes appropriate clinical referrals, as necessary.

### Study arms

For comparison with the WGS arms, the control arms approximate the standard of care for the two clinical scenarios under study. In routine primary care, the standard of care for identifying the risk of heritable conditions is a general family history assessment. In our cardiomyopathy practice, the standard of care is a family history assessment plus consideration of targeted genetic testing for cardiomyopathy. At the baseline visit of the MedSeq Project, patient participants complete a customized version of the US Surgeon General's "My Family Health Portrait" web tool [31] to document the diseases diagnosed among their family members. This web tool generates a family history summary based on the patient-entered data. The tool's designers developed a workflow unique to our study that securely transmits each patient participant's family history summary to the study staff, who forwards it to the patient's participating physician. Physician participants also receive six clinical decision support modules to accompany the family history summary for each patient, to assist them in interpreting and managing their patients' heritable risk of breast and colon cancer, coronary artery disease, type 2 diabetes, glaucoma, and osteoporosis. Patient participants in the control arms undergo only the family history review with their physicians, whereas patient participants randomly assigned to the WGS arms review both their family history summaries and WGS results with their physicians.

### Physician education and support

Many physicians feel ill prepared to address genomic medicine in their clinical practices [32-35], but the current size of the genetics workforce makes it impractical to have a genetic counselor or medical geneticist involved in every instance of genomic medicine as more and more patients are sequenced [36-38]. Moreover, as genomic medicine finds utility in an increasing number of clinical contexts, the most appropriate place for the integration of genomic information may be the existing physician-patient relationship. That is, preventive medicine for healthy adults appropriately belongs in primary care, and the management of diseases such as cardiomyopathy belongs in cardiology. To address the low self-efficacy in genomic medicine that many physicians report, the MedSeq Project provides participating PCPs and cardiologists with an

orientation to the study protocol and genome report at the beginning of the study. The educational curriculum consists of two 1-hour in-person group classes and 4 hours of self-paced online modules. The curriculum uses case-based examples to cover general genetics concepts such as inheritance patterns, an overview of Mendelian conditions, genome-wide association studies and risk of common complex diseases, and pharmacogenomics. Participants may receive continuing medical education credits for participation. The MedSeq Project also offers individualized support to physician participants during the course of the study. The MedSeq Project Genome Resource Center (GRC) links physician participants via telephone or e-mail to genetics counselors and medical geneticists affiliated with the study, in a manner similar to hotlines provided by state laboratories to support pediatricians with questions about newborn screening results. Physician participants have the option to contact the GRC with specific questions about the genome reports or family history summaries of their participating patients but are not required to do so. The GRC staff records the reasons that physician participants contact the GRC and any recommendations or actions the GRC staff takes as a result, using a web-based logbook with RedCap™ software [39].

### Whole genome sequencing and analysis

The MedSeq Project models the delivery of WGS in a traditional clinical setting. That is, as in other tests ordered in clinical care, a molecular genetics laboratory analyzes and interprets the WGS data and delivers a report to the physician, who then discusses the results with the patient and develops a management strategy. For the MedSeq Project, genome sequencing is performed at the Illumina Clinical Services Laboratory (San Diego, CA, USA) on the HiSeq 2000 platform [40]. Genomes are sequenced to at least 30× mean coverage, with a minimum of 95% of bases sequenced to at least 8× coverage. Two blood samples are collected from each patient participant; one is sent directly to Illumina for sequencing, and the other is retained by the Laboratory for Molecular Medicine (LMM) for individual variant confirmation, as needed. Once sequencing is complete, Illumina transfers the sequence alignment and variant calling data to the LMM for further analysis via an encrypted hard drive. All analyses are performed in laboratories approved by Clinical Laboratory Improvement Amendments (CLIA).

The data files from each individual genome contain approximately 3 million variants. Geneticists at the LMM prioritize the variants from each genome for further analysis by using two different bioinformatics filtering strategies. The Genome Report filter identifies (a) variants classified as disease-causing mutations in the Human Gene Mutation Database (HGMD) (professional version)



[41]; (b) nonsense, frameshift, and  $\pm 1,2$  canonical splice-site variants with a minor allele frequency of less than 5% in European American or African American chromosomes from the National Heart, Lung and Blood Institute Exome Sequencing Project [42]; (c) pharmacogenomic variants associated with commonly used medications; and (d) a subset of blood group antigens predicted by the genome sequence and confirmed via traditional serological testing of a separate patient sample. In addition, patients in the cardiomyopathy arm have another filter applied, which identifies all variants in 102 preselected monogenic cardiovascular disease genes. This includes variants that would not be identified in filters (a) and (b) above. In the Cardiac Risk Supplement, genotypes at a number of predefined loci are returned for use in algorithms to define risk status for common complex cardiovascular phenotypes.

The LMM staff reviews the scientific evidence for disease causality for each variant that results from the filtering strategies above, with the exception of the predefined set of pharmacogenomics variants and common non-Mendelian risk variants for common complex cardiovascular phenotypes. For candidate monogenic disease variants, analysis components include genetic and functional evidence from primary scientific literature, allele frequency, conservation of affected amino acid or nucleotide (or both), affected protein domain, pathogenicity predictions, and splicing predictions. Finally, each variant is classified according to LMM criteria for pathogenicity [43]. Variants meeting criteria for report inclusion as discussed in the subsequent section are confirmed via a traditional Sanger sequencing method using extracted DNA from the blood sample retained by the LMM.

### The genome report

In the MedSeq Project, the LMM delivers WGS results to physician participants as a Genome Report and a

more exploratory Cardiac Risk Supplement, both described below (Table 2) and exemplified in Additional files 1 and 2. Because the target audience of these reports consists of busy clinicians with variable expertise in genetics, the results of the Genome Report are completely summarized on the first page of the report, and subsequent pages contain greater detail about each reported variant. The Genome Report includes results of more general significance, including known pathogenic or likely pathogenic Mendelian variants, carrier status for Mendelian diseases, and known pharmacogenomics associations for five commonly used medications. Owing to the low prior probability of Mendelian disease among the patient participants, variants of uncertain significance (VUSs) in known Mendelian genes are included on the Genome Report if available evidence favors pathogenicity and if clinical follow-up may resolve the variant's significance or if the variant is in a gene associated with the etiology of the patient participant's disease (HCM or DCM). Because of the frequency of clinical decision-making around cardiovascular disease prevention in primary care, we are using the Cardiac Risk Supplement and cardiovascular disease to explore a wider range of uncertainty in clinical utility than is present for established Mendelian genes. Thus, to supplement the Genome Report, the Cardiac Risk Supplement contains common alleles associated with eight cardiometabolic traits from genome-wide association studies (GWAS), such as coronary artery disease, type 2 diabetes, and atrial fibrillation. We are also piloting the use of a polygenic prediction model for lipid levels.

For the cardiometabolic phenotypes known to be relevant both to primary care and cardiology practice, we use GWAS results to aggregate risk information across independent loci to convey a single summary of one's genetic risk for a given trait. For each trait, the Cardiac

**Table 2 Categories of whole genome sequencing results that may be included in the genome report and cardiac risk supplement in the MedSeq project**

Genome report	Cardiac risk supplement
Known pathogenic or likely pathogenic Mendelian variants, including some high-grade variants of uncertain significance resolvable by clinical evaluation	Predicted lipid profile (fasting low-density lipoprotein and high-density lipoprotein cholesterol and triglycerides) derived from polygenic model
Carrier status for Mendelian diseases	Aggregate genetic risk associated with eight cardiometabolic traits from genome-wide association studies
Pharmacogenomic associations for five commonly used medications:	Aortic aneurysm
Warfarin	Atrial fibrillation
Clopidogrel	Coronary artery disease
Digoxin	Hypertension
Metformin	Obesity
Simvastatin	Platelet aggregation
Genetic prediction of blood type with partial serological confirmation	QT prolongation
	Type 2 diabetes

Risk Supplement provides multiplicative polygenic risk scores (MPRSs) derived from 161 published risk alleles with small or moderate effects sizes (median odds ratio 1.14). We calculate the MPRS as the product of the odds ratios per risk allele at each of several loci, each raised to its count (*that is*, 0, 1, or 2). The Cardiac Risk Supplement communicates this risk as a polygenic relative risk and its decile after normalizing the MPRS by the population median from the 379 Europeans in the 1000 Genomes Project [44].

Neither the Genome Report nor its Cardiac Risk Supplement includes specific clinical recommendations on follow-up testing or referrals. This is consistent with typical clinical laboratory reports and important for the goals of the MedSeq Project, as we hope to understand how clinicians contextualize and use such information in their practices. The format of the report may evolve over the course of the study, depending on feedback from the physician participants, advances in genomic discovery, and the emergence of more robust population data on which to base clinical risk prediction. Reports are generated by using the GeneInsight Laboratory software system and transmitted to the GeneInsight Clinic system, which is integrated with our institution's electronic health record (EHR) [45].

### Study schema

Figure 1 shows the study flow and data collection points of the MedSeq Project. At the baseline visit with study staff, patient participants complete the baseline surveys and online family history assessment, undergo a blood draw, and are block-randomized to either the WGS or control arm. In the primary care trial, randomization is sex-matched. In the cardiology trial, randomization is stratified on the basis of previous targeted genetic testing results, such that a known pathogenic variant will have already been identified in approximately half of each randomized arm. No molecular diagnosis has been made for the remaining half, despite their having also undergone targeted cardiomyopathy genetic testing as a part of clinical care.

Once a patient's family history summary and Genome Report are prepared, generally after a couple of months, they are sent to the physician participant, who then has the option of contacting the GRC for assistance in interpreting the results. The study staff schedules a one-on-one disclosure visit between the patient and physician participants. At this disclosure visit, the patient learns whether he or she was randomly assigned to receive WGS. The patient discusses with his or her physician the findings in the family history summary and, if randomly assigned to receive WGS, the Genome Report. The physician and patient

make management decisions about these findings as they would in usual clinical care, which may include pursuing additional follow-up testing or referrals to subspecialists. The physician participant documents the family history and WGS information and the related clinical decision-making in the EHR as he or she feels appropriate. The disclosure visits are audio-recorded for qualitative analysis of physician-patient communication.

Within 1 week after this visit, physician participants are prompted by e-mail to complete a brief RedCap™-based checklist of the clinical actions they made as a result of the family history summary and Genome Report for a given patient. Patient participants are surveyed immediately after the disclosure visit and 6 weeks and 6 months after disclosure. A subset of 40 patient participants (approximately 10 in each arm of the two trials) undergoes semi-structured interviews at enrollment and then 6 months after their disclosure visits. Each physician participant undergoes an interview at the beginning of the study before patient enrollment and then again after conducting several disclosure visits.

### Study outcomes

The MedSeq Project is leveraging multidisciplinary expertise and a diverse set of tools to collect and analyze data on patients and physicians about a variety of outcomes. Study outcomes focus on six broad domains identified as research priority areas across studies funded by the National Human Genome Research Institute (NHGRI): (a) attitudes and preferences, (b) understanding, (c) psychological impact, (d) behavioral impact, (e) health-care utilization, and (f) decisional satisfaction. When available, we use validated instruments and harmonize the measurements across other NHGRI-funded studies of the application of genome sequencing to clinical care. Longitudinal measurements of many of these domains allow us to examine changes over the study period. Table 3 summarizes the specific outcomes being assessed for each of these domains and the data sources used. Data collection, including questionnaires, interviews, and audio-recorded interactions with patients, is performed at multiple time points. Paper and web-based surveys of patient and physician participants provide self-reported quantitative data about beliefs, attitudes, expectations, psychological states, and intentions. Semi-structured interviews with patients and physician participants allow both groups to describe in their own words their motivations for participation, their attitudes and expectations, and how they responded to results. Audio recordings of the informed consent process and the results disclosure encounter provide *in vivo* data about the kinds of questions that arise and issues that are discussed around WGS. Physician checklists after each disclosure visit, logbooks of

**Table 3 Patient- and physician-oriented outcomes by domain and data source in the MedSeq project**

	Data source							
	Patient surveys	Patient interviews	Physician surveys	Physician interviews	Physician checklist	Audio recordings	EHR review	GRC logbook
<b>Attitudes and preferences</b>								
Attitudes about project [48]	✓	✓		✓				
Attitudes about sequencing [13]	✓	✓		✓				
Perceived utility	✓	✓	✓	✓	✓			
Preferences for information	✓	✓						
<b>Understanding</b>								
Understanding of consent [49,50]	✓	✓	✓	✓		✓		
Understanding of results	✓	✓				✓		
Genetic self-efficacy [51]	✓		✓					
Genetic literacy [52]	✓	✓	✓	✓				
Health and risk perceptions [53]	✓							
<b>Psychological impact</b>								
General anxiety and depression [30]	✓							
Results-specific affect [54]	✓							
Intolerance of uncertainty [55]	✓							
<b>Behavioral impact</b>								
Health behaviors and intentions [56]	✓	✓			✓			
Insurance coverage [57]	✓	✓						
Medication and supplement use	✓	✓			✓		✓	
Information seeking and sharing [58]	✓	✓		✓	✓			✓
<b>Health-care utilization</b>								
Willingness to pay	✓		✓					
Shared decision-making [59]	✓	✓		✓		✓		
Follow-up testing and screening [60]	✓	✓		✓	✓	✓	✓	✓
<b>Decisional satisfaction</b>								
Satisfaction [61]	✓	✓		✓				
Decisional regret [62]	✓	✓		✓				
Expectations	✓	✓		✓				

References indicate published scales used in the design of the data collection instruments for the MedSeq Project. EHR, electronic health record; GRC, Genome Resource Center.

physician interactions with the GRC, and reviews of patient participant EHR data provide additional information about service utilization, information seeking, and health status. We believe this mixed-methods approach allows us to achieve significant depth in chronicling the impact of WGS information in the present trial while simultaneously developing processes that will inform the design of future trials. The MedSeq Project Publications Subcommittee has established guidelines for publications and presentations and will review all publications and presentations for consistency with these guidelines and will make recommendations to the Executive Committee regarding the dissemination of study results to relevant stakeholder groups. We will report results according to the CONSORT Statement and its

extension for non-pharmacologic treatment interventions and will include a description of how missing data were handled [46,47].

### Discussion

The MedSeq Project consists of two randomized controlled trials designed to model two archetypal situations in genomic medicine and study the impact of integrating genome sequencing into patient care. In the cardiology trial, we want to know how WGS, with a particular focus on cardiac risk information, might alter the ongoing clinical management of cardiomyopathy patients. The cardiology trial also allows us to study how physicians and patients manage incidental genomic findings not directly related to the original reason for genetic testing [27]. In



the primary care trial, we want to know how WGS might shape the attitudes, behaviors, and health care of generally healthy individuals. To answer these questions, we have developed a scalable pipeline to analyze and interpret WGS results and deliver a clinically useful genome report to physicians caring for these patients. We provide non-geneticist physician participants with educational and consultative resources that we believe comprise a workable model to support their use of genomic medicine in an era when the demand for genetics specialists exceeds supply.

The design of the MedSeq Project reflects many of the competing priorities inherent in a study of integrating WGS into clinical practice. We know that the field of genomics itself is rapidly evolving over the course of the study, let alone by the time the study's results are ready for dissemination. This evolution is occurring on many fronts: improvements in sequencing quality, decreasing costs and time necessary to perform sequencing, increasing clinical experience with WGS at many academic medical centers, and continual publication of newly discovered genes and variants linked to human disease. Meanwhile, we are limited by the present technology, costs, and knowledge at the time of study design. We understand that the study of such a moving target risks the collection of results that could rapidly become obsolete, and thus we have modeled processes for the integration of WGS into clinical medicine both now and in the near future. For example, while we are generating genome reports based on the current state of the science and delivering them to the physician-patient encounter, we plan to allow the format and content of these reports to evolve with the field, incorporating new discoveries and refining our interpretations of pathogenicity and utility. We hope to create a paradigm for the clinical integration of WGS which will remain relevant even as genomic medicine advances in technology and content.

We also are attempting to integrate the clinical uncertainty that necessarily accompanies results from WGS, particularly in healthy adults, and at the same time present a meaningful genome report to physicians and their patients. When clinical significance is uncertain, the report will have to acknowledge and communicate this uncertainty effectively, allowing the physician to contextualize the information for the individual patient. This tension necessitates finding the right balance between embracing the ambiguity of WGS results and limiting the scope of what is reported to physician and patient participants. The importance of cardiovascular disease in primary and subspecialty care has prompted us to explore, through the Cardiac Risk Supplement, a greater degree of genomic uncertainty in that disease area as a demonstration of integrating GWAS-type results into clinical care.

In addition, we seek to balance the tensions of providing enough support to participating physicians while minimizing the burden to the limited genetics referral resources available at most medical centers. We have designed the MedSeq Project with the premise that all physicians will soon have to manage at least some genomic information in their practices. Thus, we have intentionally not provided a level of counseling or consultant support that would make our model logistically or economically unsustainable as WGS is increasingly introduced to the clinical context. Still, we acknowledge the need to provide at least some educational and consultation support, both to ensure the quality of care in this novel situation and to monitor for patient safety. We believe that the product of these tensions, the MedSeq Project educational curriculum and Genome Resource Center, represents a workable model for physician support in genomic medicine research, with potential for scaling to routine clinical use.

Our study has some limitations inherent in a trial of this nature. Because we are studying the way that new genomic information is used in clinical care, we cannot blind our patient and physician participants to their randomization status. Unblinded randomized controlled trials may be biased by changes in patient and physician behaviors and outcomes unrelated to the effect of the intervention studied. In our case, however, these changes in behaviors and outcomes are precisely what we are interested in studying. Similarly, our researchers are not blinded to patient randomization. For this reason, our use of objective survey instruments and EHR data is particularly helpful in comparing those who received WGS with those who did not. Finally, each physician participant in the study will have patients in each of the two study arms. Our results will therefore have to be interpreted with the risk that patient outcomes may be correlated with physician behavior in mind. As appropriate, we will perform certain analyses with clustering by physician to account for these possible within-physician effects.

The MedSeq Project is the first randomized controlled trial of WGS in clinical care. We are using a multidisciplinary team of laboratory and clinical geneticists, bioinformaticians, biostatisticians, clinicians, and social scientists to study the many ways that WGS will impact patient care in two archetypal clinical scenarios: disease-specific genomic medicine and general genomic medicine. We expect to produce quantitative and qualitative data that inform the ongoing real-time clinical integration of WGS and also generate novel hypotheses to inform the design of larger studies moving forward. Our considerations of how best to present complex but clinically relevant information derived from WGS to physicians and their patients and measure its impact on clinical care should remain instructive for future research in genomic medicine.

## Trial status

Physician and patient participants were being enrolled as of March 2014.

## Additional files

**Additional file 1: Figure S1.** Sample Genome Report.

**Additional file 2: Figure S2.** Sample Cardiac Risk Supplement.

## Abbreviations

DCM: dilated cardiomyopathy; EHR: electronic health record; GRC: Genome Resource Center; GWAS: genome-wide association study; HADS: hospital anxiety and depression scale; HCM: hypertrophic cardiomyopathy; LMM: laboratory for molecular medicine; MPRS: multiplicative polygenic risk score; NHGRl: National Human Genome Research Institute; PCP: primary care physician; VUS: variant of uncertain significance; WGS: whole genome sequencing.

## Competing interests

CAM receives a modest royalty income from genetic testing for cardiomyopathies. HLR and HMM are employed by Partners Healthcare, which offers fee-for-service molecular diagnostic services (Laboratory for Molecular Medicine) and software licensing (Genelinsight). HLR also serves on compensated advisory boards for Complete Genomics (Mountain View, CA, USA), Knome (Cambridge, MA, USA), and Ingenuity (Redwood City, CA, USA). All other authors declare that they have no competing interests.

## Authors' contributions

JLV made a substantial contribution to study design and wrote the manuscript. DML, KDC, JK, ISK, LZ, JB-B, JSR, LSL, CYH, PAU, CAM, CES, MFM, ALM, HLR, and RCG each made substantial contributions to the study design and revised the manuscript. HLR, HMM, and SWK made substantial contributions to the genome analysis and interpretation process and genomic report design and edited the manuscript. All authors read and approved the final manuscript.

## Acknowledgments

The MedSeq Project is supported by the National Institutes of Health (NIH) National Human Genome Research Institute (U01-HG006500). JLV is supported by NIH L30 DK089597. KDC is supported by NIH F32 HG006993. JK is supported by NIH T32 GM007748-34. The project described was supported by Clinical Translational Science Award UL1RR025758 to Harvard University and Brigham and Women's Hospital from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The authors thank 5AM Solutions, Inc. (Rockville, MD, USA), for their help in customizing the workflow of the "My Family Health Portrait" web tool for this study.

<sup>‡</sup>Members of the MedSeq Project are as follows: David W. Bates, MD; Alexis D. Carere, MA, MS; Allison Cirino, MS; Lauren Connor, Kurt D. Christensen, MPH, PhD; Jake Duggan, Robert C. Green, MD, MPH; Carolyn Y. Ho, MD; Joel B. Krier, MD; William J. Lane, MD, PhD; Denise M. Lautenbach, MS; Lisa Lehmann, MD, PhD, MSc; Christina Liu, Calum A. MacRae, MD, PhD; Rachel Miller, MA; Cynthia C. Morton, PhD; Christine E. Seidman, MD; Shamil Sunyaev, PhD; Jason L. Vassy, MD, MPH, SM, Brigham and Women's Hospital and Harvard Medical School; Sandy Aronson, ALM, MA; Ozge Ceyhan-Birsoy, PhD; Siva Gowrisankar, PhD; Matthew S. Lebo, PhD; Ignat Leschiner, PhD; Kalotina Machini, PhD, MS; Heather M. McLaughlin, PhD; Danielle R. Metterville, MS; Heidi L. Rehm, PhD, Partners Center for Personalized Genetic Medicine; Jennifer Blumenthal-Barby, PhD; Lindsay Zausmer Feuerman, Amy L. McGuire, JD, PhD; Sarita Panchang, Jill Oliver Robinson, MA; Melody J. Slashinski, MPH, PhD, Baylor College of Medicine, Center for Medical Ethics and Health Policy; Stewart C. Alexander, PhD; Kelly Davis, Peter A. Ubel, MD, Duke University; Peter Kraft, PhD, Harvard School of Public Health; J. Scott Roberts, PhD, University of Michigan; Judy E. Garber, MD, MPH, Dana-Farber Cancer Institute; Tina Hambuch, PhD, Illumina, Inc.; Michael F. Murray, MD, Geisinger Health System; Isaac S. Kohane, MD, PhD; Sek Won Kong, MD; In-Hee Lee, PhD, Boston Children's Hospital.

## Author details

<sup>1</sup>Section of General Internal Medicine, VA Boston Healthcare System, 150 S Huntington Ave, Boston, MA 02130, USA. <sup>2</sup>Department of Medicine, Harvard Medical School, 150 South Huntington Avenue 152G, Boston, MA 02130, USA. <sup>3</sup>Division of Genetics, Department of Medicine, Brigham and Women's Hospital, 41 Avenue Louis Pasteur, Suite 301, Boston, MA 02115, USA. <sup>4</sup>Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine, 65 Landsdowne St., Cambridge, MA 02139, USA. <sup>5</sup>Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA. <sup>6</sup>Department of Medicine, Boston Children's Hospital, 300 Longwood Ave, EN137, Boston, MA 02115, USA. <sup>7</sup>Department of Pediatrics, Harvard Medical School, 41 Avenue Louis Pasteur, Suite 301, Boston, MA 02115, USA. <sup>8</sup>Center for Biomedical Informatics & Department of Pediatrics, Harvard Medical School, 300 Longwood Ave, Enders-6, Boston, MA 02115, USA. <sup>9</sup>Center for Medical Ethics and Health Policy, Baylor College of Medicine, BCM-Jewish Institute for Research, Houston, TX 77030, USA. <sup>10</sup>Department of Health Behavior & Health Education at University of Michigan School of Public Health, 109 S. Observatory, SPH I Building, Room 3854, Ann Arbor, MI 48109, USA. <sup>11</sup>Center for Bioethics, Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 03-002, Room BC3-2G, Boston, MA 02120, USA. <sup>12</sup>Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA. <sup>13</sup>Fuqua School of Business, Duke University, 100 Fuqua Drive, Durham, NC 27708, USA. <sup>14</sup>Department of Genetics, Harvard Medical School, NRB-room 256 77 Avenue Louis Pasteur, Boston, MA 02115, USA. <sup>15</sup>Genomic Medicine Institute, Geisinger Health System, 1000 East Mountain Drive, Wilkes Barre, PA 18711, USA. <sup>16</sup>Genomes2People and Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute and Harvard Medical School, 41 Avenue Louis Pasteur, Suite 301, 02115 Boston, MA, USA.

Received: 26 November 2013 Accepted: 28 February 2014

Published: 20 March 2014

## References

1. *The Human Genome Project Completion: Frequently Asked Questions.* [http://www.genome.gov/11006943]
2. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, Serpe JM, Dasu T, Tschannen MR, Veith RL, Basehore MJ, Broeckel U, Tomita-Mitchell A, Arca MJ, Casper JT, Margolis DA, Bick DP, Hessner MJ, Routes JM, Verbsky JW, Jacob HJ, Dimmock DP: **Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease.** *Genet Med* 2011, **13**:255-262.
3. Knies K, Schuster B, Ameziane N, Rooimans M, Bettecken T, de Winter J, Schindler D: **Genotyping of Fanconi anemia patients by whole exome sequencing: advantages and challenges.** *PLoS One* 2012, **7**:e52648.
4. Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I, Reid JG, Fink JK, Morgan MB, Gingras MC, Muzny DM, Hoang LD, Youssaf S, Lupski JR, Gibbs RA: **Whole-genome sequencing for optimized patient management.** *Sci Transl Med* 2011, **3**:87re83.
5. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK: **Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.** *Blood* 2012, **120**:1060-1066.
6. Saunders CJ, Miller NA, Soden SE, Dinwiddie DL, Noll A, Alnadi NA, Andraws N, Patterson ML, Krivohlavek LA, Fellis J, Humphray S, Saffrey P, Kingsbury Z, Weir JC, Betley J, Grocock RJ, Margulies EH, Farrow EG, Artman M, Safina NP, Petrikon JE, Hall KP, Kingsmore SF: **Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units.** *Sci Transl Med* 2012, **4**:154ra135.
7. Talkowski ME, Ordulu Z, Pillalamarri V, Benson CB, Blumenthal I, Connolly S, Hanscom C, Hussain N, Pereira S, Picker J, Rosenfeld JA, Shaffer LG, Wilkins-Haug LE, Gusella JF, Morton CC: **Clinical diagnosis by whole-genome sequencing of a prenatal sample.** *N Engl J Med* 2012, **367**:2226-2232.
8. Altman RB: **Personal genomic measurements: the opportunity for information integration.** *Clin Pharmacol Ther* 2013, **93**:21-23.

9. Green RC, Rehm HL, Kohane IS: **Clinical genome sequencing.** In *Genomic and Personalized Medicine. Vol. 1.* 2nd edition. Waltham, PA: Academic Press; 2013:102–122.
10. Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, Braxton A, Beuten J, Xia F, Niu Z, Hardison M, Person R, Bekheirnia MR, Leduc MS, Kirby A, Pham P, Scull J, Wang M, Ding Y, Plon SE, Lupski JR, Beaudet AL, Gibbs RA, Eng CM: **Clinical whole-exome sequencing for the diagnosis of mendelian disorders.** *N Engl J Med* 2013, **369**:1502–1511.
11. *Catalog of Published Genome-Wide Association Studies.* [http://www.genome.gov/gwastudies/]
12. Goldberger JJ, Buxton AE: **Personalized medicine vs guideline-based medicine.** *JAMA* 2013, **309**:2559–2560.
13. McGuire AL, Diaz CM, Wang T, Hilsenbeck SG: **Social networkers' attitudes toward direct-to-consumer personal genome testing.** *Am J Bioeth* 2009, **9**:3–10.
14. Kohane IS, Masys DR, Altman RB: **The incidentalome: a threat to genomic medicine.** *JAMA* 2006, **296**:212–215.
15. McGuire AL, Burke W: **An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons.** *JAMA* 2008, **300**:2669–2671.
16. Green E, Guyer M: **Charting a course for genomic medicine from base pairs to bedside.** *Nature* 2011, **470**:204–213.
17. Khoury MJ, McCabe LL, McCabe RB: **Population screening in the age of genomic medicine.** *N Engl J Med* 2003, **348**:50–58.
18. Khoury M, Berg A, Coates R, Evans J, Teutsch S, Bradley L: **The evidence dilemma in genomic medicine.** *Health Aff* 2008, **27**:1600–1611.
19. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N: **Analysis of circulating tumor DNA to monitor metastatic breast cancer.** *N Engl J Med* 2013, **368**:1199–1209.
20. Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, Bainbridge M, Dinh H, Jing C, Wheeler DA, McGuire AL, Zhang F, Stankiewicz P, Halperin JJ, Yang C, Gehman C, Guo D, Irikat RK, Tom W, Fantinicz M, Muzny DM, Gibbs RA: **Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy.** *N Engl J Med* 2010, **362**:1181–1191.
21. Maxmen A: **Exome sequencing deciphers rare diseases.** *Cell* 2011, **144**:635–637.
22. Quaynor SD, Stradtman EW Jr, Kim HG, Shen Y, Chorich LP, Schreihof DA, Layman LC: **Delayed puberty and estrogen resistance in a woman with estrogen receptor alpha variant.** *N Engl J Med* 2013, **369**:164–171.
23. Koser CU, Bryant JM, Becq J, Torok ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ: **Whole-genome sequencing for rapid susceptibility testing of *M. tuberculosis*.** *N Engl J Med* 2013, **369**:290–292.
24. Köser CU, Holden MT, Ellington MJ, Cartwright EJ, Brown NM, Ogilvy-Stuart AL, Hsu LY, Chewapreecha C, Croucher NJ, Harris SR, Sanders M, Enright MC, Dougan G, Bentley SD, Parkhill J, Fraser LJ, Betley JR, Schulz-Trieglaff OB, Smith GP, Peacock SJ: **Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak.** *N Engl J Med* 2012, **366**:2267–2275.
25. Loman NJ, Constantinoiu C, Christner M, Rohde H, Chan JZ, Quick J, Weir JC, Quince C, Smith GP, Betley JR, Aepfelbacher M, Pallen MJ: **A culture-independent sequence-based metagenomics approach to the investigation of an outbreak of shiga-toxicogenic *Escherichia coli* O104:H4.** *JAMA* 2013, **309**:1502–1510.
26. Crotti L, Tester DJ, White WM, Bartos DC, Insolia R, Besana A, Kunic JD, Will ML, Velasco EJ, Bair JJ, Ghidoni A, Cetin I, Van Dyke DL, Wick MJ, Brost B, Delisle BP, Facchinetti F, George AL, Schwartz PJ, Ackerman MJ: **Long QT syndrome-associated mutations in intrauterine fetal death.** *JAMA* 2013, **309**:1473–1482.
27. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG: **ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.** *Genet Med* 2013, **15**:565–574.
28. Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Rosenthal EA, Kim DS, Tabor HK, Bamshad MJ, Motulsky AG, Scott CR, Pritchard CC, Walsh T, Burke W, Raskind WH, Byers P, Hisama FM, Nickerson DA, Jarvik GP, National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project: **Actionable, pathogenic incidental findings in 1,000 participants' exomes.** *Am J Hum Genet* 2013, **93**:631–640.
29. *Laboratory for Molecular Medicine variant classification rules.* [http://pcpgm.partners.org/sites/default/files/LMM/Resources/LMM\_VariantClassification\_05.26.11.pdf]
30. Zigmond AS, Snaith RP: **The hospital anxiety and depression scale.** *Acta Psychiatr Scand* 1983, **67**:361–370.
31. *My Family Health Portrait: A Tool from the Surgeon General.* [https://familyhistory.hhs.gov/fhh-web/home.action]
32. Nippert I, Harris HJ, Julian-Reynier C, Kristofferson U, Ten Kate LP, Anionwu E, Benjamin C, Challen K, Schmidtke J, Nippert RP, Harris R: **Confidence of primary care physicians in their ability to carry out basic medical genetic tasks—a European survey in five countries—Part 1.** *J Community Genet* 2011, **2**:1–11.
33. Najafzadeh M, Lynd LD, Davis JC, Bryan S, Anis A, Marra M, Marra CA: **Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment.** *Genet Med* 2012, **14**:520–526.
34. Selkirk CG, Weissman SM, Anderson A, Hulick PJ: **Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system.** *Genet Test Mol Biomarkers* 2013, **17**:219–225.
35. Scheuner MT, Sieverding P, Shekelle PG: **Delivery of genomic medicine for common chronic adult diseases: a systematic review.** *JAMA* 2008, **299**:1320–1334.
36. Korf BR, Ledbetter D, Murray MF: **Report of the banbury summit meeting on the evolving role of the medical geneticist, February 12–14, 2006.** *Genet Med* 2008, **10**:502–507.
37. Cooksey JA, Forte G, Benkendorf J, Blitzer MG: **The state of the medical geneticist workforce: findings of the 2003 survey of American Board of Medical Genetics certified geneticists.** *Genet Med* 2005, **7**:439–443.
38. Association of American Medical Colleges Center for Workforce Studies: *Recent Studies and Reports on Physician Shortages in the US.* Washington, DC: Association of American Medical Colleges Center for Workforce Studies; 2012.
39. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: **Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support.** *J Biomed Inform* 2009, **42**:377–381.
40. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karvelashvili MS, Kirk SM, Li H, Liu X, Masinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT: **Accurate whole human genome sequencing using reversible terminator chemistry.** *Nature* 2008, **456**:53–59.
41. Cooper DN, Stenson PD, Chuzhanova NA: **The human gene mutation database (HGMD) and its exploitation in the study of mutational mechanisms.** *Curr Protoc Bioinformatics* 2006, **Chapter 1**:Unit 1 13.
42. *NHLBI Exome Sequencing Project (ESP): Exome Variant Server.* [http://evs.gs.washington.edu/EVS/]
43. Duzkale H, Shen J, McLaughlin H, Alfares A, Kelly M, Pugh T, Funke B, Rehm H, Lebo M: **A systematic approach to assessing the clinical significance of genetic variants.** *Clin Genet* 2013, **84**:453–463.
44. Via M, Gignoux C, Burchard E: **The 1000 genomes project: new opportunities for research and social challenges.** *Genome Med* 2010, **2**:3.
45. Aronson SJ, Clark EH, Babb LJ, Baxter S, Farwell LM, Funke BH, Hernandez AL, Joshi VA, Lyon E, Parthum AR, Russell FJ, Varugheese M, Venman TC, Rehm HL: **The GeneSight suite: a platform to support laboratory and provider use of DNA-based genetic testing.** *Hum Mutat* 2011, **32**:532–536.
46. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P: **Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration.** *Ann Intern Med* 2008, **148**:295–309.
47. Schulz KF, Altman DG, Moher D: **CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.** *Ann Intern Med* 2010, **152**:726–732.
48. Hall MA, Camacho F, Lawlor JS, Depuy V, Sugarman J, Weinfurt K: **Measuring trust in medical researchers.** *Med Care* 2006, **44**:1048–1053.
49. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC: **Quality of informed consent: a new measure of understanding among research subjects.** *J Natl Cancer Inst* 2001, **93**:139–147.
50. O'Connor AM: **Validation of a decisional conflict scale.** *Med Decis Making* 1995, **15**:25–30.
51. Kaphingst KA, McBride CM, Wade C, Alford SH, Reid R, Larson E, Baxevanis AD, Brody LC: **Patients' understanding of and responses to multiplex genetic susceptibility test results.** *Genet Med* 2012, **14**:681–687.

52. Kaphingst KA, Facio FM, Cheng MR, Brooks S, Eidem H, Linn A, Biesecker BB, Biesecker LG: **Effects of informed consent for individual genome sequencing on relevant knowledge.** *Clin Genet* 2012, **82**:408–415.
53. DeSalvo KB, Fan VS, McDonnell MB, Fihn SD: **Predicting mortality and healthcare utilization with a single question.** *Health Serv Res* 2005, **40**:1234–1246.
54. Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C: **A brief assessment of concerns associated with genetic testing for cancer: the multidimensional impact of cancer risk assessment (MICRA) questionnaire.** *Health Psychol* 2002, **21**:564–572.
55. Carleton RN, Norton MA, Asmundson GJ: **Fearing the unknown: a short version of the intolerance of uncertainty scale.** *J Anxiety Disord* 2007, **21**:105–117.
56. Prochaska JO: **Decision making in the transtheoretical model of behavior change.** *Med Decis Making* 2008, **28**:845–849.
57. Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC: **Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.** *Health Aff (Millwood)* 2005, **24**:483–490.
58. Nelson D, Kreps G, Hesse B, Croyle R, Willis G, Arora N, Rimer B, Vish Viswanath K, Weinstein N, Alden S: **The health information national trends survey (HINTS): development, design, and dissemination.** *J Health Commun* 2004, **9**:443–460.
59. Degner LF, Sloan JA, Venkatesh P: **The control preferences scale.** *Can J Nurs Res* 1997, **29**:21–43.
60. Behavioral Risk Factor Surveillance System: *Centers for Disease Control and Prevention.* [[http://www.cdc.gov/brfss/annual\\_data/pdf-ques/2009brfss.pdf](http://www.cdc.gov/brfss/annual_data/pdf-ques/2009brfss.pdf)]
61. Roter D, Larson S: **The Roter interaction analysis system (RIAS): utility and flexibility for analysis of medical interactions.** *Patient Educ Couns* 2002, **46**:243–251.
62. Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, Feldman-Stewart D: **Validation of a decision regret scale.** *Med Decis Making* 2003, **23**:281–292.

doi:10.1186/1745-6215-15-85

**Cite this article as:** Vassy et al.: The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. *Trials* 2014 **15**:85.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)





**Name:DOE, JONATHAN**

DOB: 12/34/5678

Sex: Male

Race: Caucasian

MRN:123456789

Specimen: Blood, Peripheral

Received: 12/34/5678

**Accession ID: PMXX-12345**

Family #: F12345

Referring physician: MedSeq

Referring facility: MedSeq

**GENERAL GENOME REPORT****RESULT SUMMARY**

Sequencing of this individual's genome was performed and covered 95.7% of all positions at 8X coverage or higher, resulting in over 5.2 million variants compared to reference genome. These data were analyzed to identify previously reported variants of potential clinical relevance as well as novel variants that could reasonably be assumed to cause disease (see methodology below). All results are summarized on page 1 with further details on subsequent pages.

**MONOGENIC DISEASE RISK: 1 VARIANT IDENTIFIED**

This test identified 1 genetic variant that may be responsible for existing disease or the development of disease in this individual's lifetime.

Disease (Inheritance)	Phenotype	Gene (Variant)	Classification
X-linked recessive chondrodysplasia punctata (X-linked)	Abnormal bone and cartilage development	ARSE (c.410G>C p.Gly137Ala)	Uncertain significance: Favor pathogenic

**CARRIER RISK: 2 VARIANTS IDENTIFIED**

This test identified carrier status for 2 autosomal recessive disorders.

Disease (Inheritance)	Phenotype	Gene (Variant)	Classification	Carrier Phenotype*
Cystic fibrosis (Autosomal recessive)	Chronic lung and digestive disease	CFTR (c.3846G>A p.Trp1282X)	Pathogenic	None Reported
Glycogen storage disease 7 (Autosomal recessive)	Severe exercise intolerance	PFKM (c.237+1G>A)	Pathogenic	None Reported

As a carrier for recessive genetic variants, this individual is at higher risk for having a child with one or more of these highly penetrant disorders. To determine the risk for this individual's future children to be affected, the partner of this individual would also need to be tested for these variants. Other biologically related family members may also be carriers of these variants. \*Carriers for some recessive disorders may be at risk for certain phenotypes. Please see variant descriptions for more information.

**PHARMACOGENOMIC ASSOCIATIONS**

This test identified the following pharmacogenomic associations. Additional pharmacogenomic results may be requested, but will require additional molecular confirmation prior to disclosure.

Drug	Risk and Dosing Information
Warfarin	Increased dose requirement
Clopidogrel	Typical response to clopidogrel
Digoxin	Intermediate metabolism and serum concentration of digoxin
Metformin	Decreased glycemic response to metformin
Simvastatin	Typical risk of simvastatin-related myopathy

**BLOOD GROUPS**

This test identified the ABO Rh Blood Type as AB Negative. Based on their results, this person is a very desirable universally compatible platelet donor. Additional RBC and platelet antigen information is available at the end of the report.

**It should be noted that the disease risk section of this report is limited only to variants with strong evidence for causing highly penetrant disease, or contributing to highly penetrant disease in a recessive manner. Not all variants identified have been analyzed, and not all regions of the genome have been adequately sequenced. These results should be interpreted in the context of the patient's medical evaluation, family history, and racial/ethnic background. Please note that variant classification and/or interpretation may change over time if more information becomes available. For questions about this report, please contact the Genome Resource Center at [GRC@partners.org](mailto:GRC@partners.org).**



**GENERAL GENOME REPORT(CONTINUED)**

**DETAILED VARIANT INFORMATION**

**MONOGENIC DISEASE RISK**

Disease (Inheritance)	Gene ( Transcript)	Variant (Classification)	Variant Frequency	Disease Prevalence	References
X-linked recessive chondrodysplasia punctata (X-linked)	ARSE (NM_000047.2)	c.410G>C p.Gly137Ala hemizygous (Uncertain significance: Favor pathogenic)	1/6728 (0.01%) European American	1:500,000	Sheffield 1998, Nino 2008, Franco 1995, Matos-Miranda 2013

**VARIANT INTERPRETATION:** The Gly137Ala variant in ARSE has been previously identified in 2 males with chondrodysplasia punctata; however, this variant was also identified in one unaffected male family member (Sheffield 1998, Nino 2008). Variants in a paralogous gene (ARSB) at the same position have also been identified in an individual with Maroteux-Lamy syndrome, which also features skeletal abnormalities (Franco 1995). Functional studies indicate that the Gly137Ala variant leads to reduced ARSE activity (Matos-Miranda 2013). In summary, although some data support a disease-causing role, there is currently insufficient evidence for pathogenicity leading to a current classification of uncertain significance.

**DISEASE INFORMATION:** X-linked chondrodysplasia punctata 1 (CDPX1), a congenital disorder of bone and cartilage development, is caused by a deficiency of the Golgi enzyme arylsulfatase E (ARSE). It is characterized by chondrodysplasia punctata (stippled epiphyses), brachytelephalangy (shortening of the distal phalanges), and nasomaxillary hypoplasia. Although most affected males have minimal morbidity and skeletal findings that improve by adulthood, some have significant medical problems including respiratory compromise, cervical spine stenosis and instability, mixed conductive and sensorineural hearing loss, and abnormal cognitive development. From GeneReviews abstract: <http://www.ncbi.nlm.nih.gov/books/NBK1544/>

**FAMILIAL RISK:** X-Linked chondrodysplasia punctata is inherited in an X-linked recessive manner, with primarily males being affected. Each child is at a 50% (or 1 in 2) chance of inheriting the variant from a carrier female, while all daughters will inherit the variant from an affected male.

**CARRIER RISK**

Disease (Inheritance)	Gene (Transcript)	Variant (Classification)	Variant Frequency	Disease Prevalence (Carrier Freq.)	References	Carrier Phenotype
Cystic fibrosis (Autosomal recessive)	CFTR (NM_000492.3)	c.3846G>A p.Trp1282X heterozygous (Pathogenic)	6/8600 (0.07%) European American	1/3200 European American (1/25)	Hamosh 1991, Kerem 1990, Shoshani 1992, Vidaud 1990	None Reported

**VARIANT INTERPRETATION:** The Trp1282X variant in CFTR has been identified in numerous patients with cystic fibrosis (Vidaud 1990, Kerem 1990, Hamosh 1991, Shoshani 1992). This variant is present on the American Board of Medical Genetics CFTR mutation panel ([http://www.acmg.net/Pages/ACMG\\_Activities/stds-2002/cf.htm](http://www.acmg.net/Pages/ACMG_Activities/stds-2002/cf.htm)). This nonsense variant leads to a premature termination codon at position 1282, which is predicted to lead to a truncated or absent protein. In summary, this variant meets our criteria for pathogenicity.

**DISEASE INFORMATION:** Cystic fibrosis affects the epithelia of the respiratory tract, exocrine pancreas, intestine, male genital tract, hepatobiliary system, and exocrine sweat glands, resulting in a complex multisystem disease. Pulmonary disease is the major cause of morbidity and mortality in CF. Affected individuals have lower airway inflammation and chronic endobronchial infection, progressing to end-stage lung disease characterized by extensive airway damage (bronchiectasis, cysts, and abscesses) and fibrosis of lung parenchyma. Meconium ileus occurs at birth in 15%-20% of newborns with CF. Pancreatic insufficiency with malabsorption occurs in the great majority of individuals with CF. More than 95% of males with CF are infertile as a result of azoospermia caused by absent, atrophic, or fibrotic Wolffian duct structures. Adapted from GeneReviews abstract: <http://www.ncbi.nlm.nih.gov/books/NBK1250/>

**FAMILIAL RISK:** Cystic fibrosis is inherited in an autosomal recessive manner. A carrier of cystic fibrosis has a 50% chance of passing on the CFTR variant to any children. The risk of this patient's child having cystic fibrosis is dependent on the CFTR carrier status of the patient's partner. This patient likely inherited the CFTR variant from one of his parents. Other biologically related family members may also be carriers of this variant.

### GENERAL GENOME REPORT(CONTINUED)

Disease (Inheritance)	Gene (Transcript)	Variant (Classification)	Variant Frequency	Disease Prevalence (Carrier Freq.)	References	Carrier Phenotype
Glycogen storage disease 7 (Autosomal recessive)	PFKM (NM_000289.5)	c.237+1G>A heterozygous Pathogenic	Not previously reported	Unknown (Unknown)	Raben 1993	None Reported

**VARIANT INTERPRETATION:** The 237+1G>A variant in PFKM has been previously identified in one homozygous patient with glycogen storage disease 7 and was found to segregate with disease in an affected homozygous relative (Raben 1993). This variant is located in the 5' splice region and computational tools do suggest an impact to splicing. In summary, this variant meets our criteria for pathogenicity.

**DISEASE INFORMATION:** Glycogen storage disease 7 is caused by a deficiency of muscle phosphofructokinase activity. Symptoms usually appear in adulthood and are characterized by exercise intolerance with muscle cramps that can be accompanied by attacks of myoglobinuria. Some patients also experience compensated hemolytic anemia and early onset myogenic hyperuricemia. In addition to the accumulation of normal glycogen in muscle, an abnormal glycogen, resembling amylopectin, can be found in some muscle fibers. Adapted from Online Metabolic and Molecular Basis of Inherited Disease abstract:

[http://www.ommbid.com//OMMBID/the\\_online\\_metabolic\\_and\\_molecular\\_bases\\_of\\_inherited\\_disease/b/abstract/part7/ch71](http://www.ommbid.com//OMMBID/the_online_metabolic_and_molecular_bases_of_inherited_disease/b/abstract/part7/ch71)

**FAMILIAL RISK:** Glycogen storage disease 7 is inherited in an autosomal recessive manner. A carrier of glycogen storage disease 7 has a 50% chance of passing on the PFKM variant to any children. The risk of this patient's child having Glycogen storage disease 7 is dependent on the PFKM carrier status of the patient's partner. This patient likely inherited the PFKM variant from one of his parents. Other biologically related family members may also be carriers of this variant.

## PHARMACOGENOMIC ASSOCIATIONS AND BLOOD GROUPS

### PHARMACOGENOMIC ASSOCIATIONS

Drug (Indication)	Summary	Variants Evaluated and Genotypes Identified	Interpretation	References
Warfarin (Anti-coagulation)	<b>Standard dose requirement</b>	CYP2C9 rs1057910 rs1799853 Genotype: c.[430C;1075A]; c.[430C>T;1075A] *1/*2  VKORC1 rs9923231 Genotype: AA	Patients with the CYP2C9*1/*2 genotype may require a lower dose of warfarin as compared to patients with the CYP2C9*1/*1 genotype. Patients with the VKORC1 AA genotype may require a lower dose of warfarin as compared to patients with the VKORC1 GG or GA genotypes. However, patients with the combination of the CYP2C9*1/*2 genotype and VKORC1 AA genotype are predicted to require standard doses of warfarin compared to other patients. Refer to warfarindosing.org for dosing based on genotype and other clinical factors.	Takeuchi 2009, Cooper 2008, International Warfarin Pharmacogenetics Consortium 2009, Margaglione 2000, Pautas 2010, Scott 2010, Verstuyft 2001

**GENERAL GENOME REPORT(CONTINUED)**

		<b>VKORC1/CYP2C9 GENOTYPE COMBINATION FREQUENCIES</b>			
		<b>Dosing Group</b>	<b>VKORC1 rs9923231</b>	<b>CYP2C9 Genotypes</b>	<b>Approximate Frequency</b>
		Lower	AA	*1/*3, *2/*2, *2/*3, *3/*3	6%
			GA	*2/*3, *3/*3	3%
		Standard	AA	*1/*1, *1/*2	37%
			GA	*1/*2, *1/*3, *2/*2	14%
			GG	*1/*3, *2/*2, *2/*3	<1%
		Higher	GA	*1/*1	28%
			GG	*1/*1, *1/*2	13%
Clopidogrel (Anti-coagulation)	<b>Typical response to clopidogrel</b>	CYP2C19 rs12248560 rs4244285 rs4986893 Genotype: *1/*1 c.[-806C(-);681G(-);636G]; c.[-806C(-);681G(-);636G]		Patients with the CYP2C19 *1/*1 genotype may have extensive (typical) metabolism of clopidogrel as well as well as typical response to clopidogrel as compared to ultrarapid or poor clopidogrel metabolizers. Additional information and dosing recommendations for this result can be found at: <a href="http://www.pharmgkb.org/drug/PA449053">http://www.pharmgkb.org/drug/PA449053</a> .	Tiroch 2010, Sim 2006, Sibbing 2010
		<b>CYP2C19 GENOTYPE FREQUENCIES</b>			
		<b>Metabolism</b>	<b>Genotypes</b>	<b>Frequency</b>	
		Ultrarapid	*1/*17, *17/*17	5-30%	
		Extensive	*1/*1	35-50%	
		Intermediate	*1/*2, *1/*3	18-35%	
		Poor	*2/*2, *2/*3, *3/*3	2-15%	
Digoxin (Dysrhythmias, heart failure)	<b>Intermediate metabolism and serum concentration of digoxin</b>	ABCB1 rs1045642 Genotype: CT  Genotype frequencies: CC:50% <b>CT:22%</b> TT:28%		Patients with the CT genotype who take oral digoxin may have intermediate metabolism and serum concentrations of digoxin as compared to patients with the CC and TT genotypes.	Aarnoudse 2008, Kurata 2002, Hoffmeyer 2000
Metformin (Type 2 diabetes mellitus)	<b>Typical glycemic response to metformin</b>	C11orf65 rs11212617 Genotype: TT  Genotype frequencies: <b>TT:37%</b> TG:48% GG:15%		Patients with the TT genotype who have Type 2 Diabetes Mellitus and are treated with metformin may have a decreased glycemic response as compared to patients with the GG genotype. An association with increased or decreased glycemic response to metformin was not seen in people diagnosed with impaired glucose tolerance in the absence of Type 2 Diabetes Mellitus.	Florez 2012, GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group 2011

### GENERAL GENOME REPORT(CONTINUED)

Drug (Indication)	Summary	Variants Evaluated and Genotypes Identified	Interpretation	References
Simvastatin (Hyperlipidemia)	<b>Typical risk of simvastatin-related myopathy</b>	SLCO1B1 rs4149056 Genotype: TT  Genotype frequencies: <b>TT:68%</b> TC:30% CC:2%	Patients with the TT genotype may have a lower risk of simvastatin-related myopathy as compared to patients with the CT or CC genotype.	Pasanen 2006, SEARCH Collaborative Group 2008, Brunham 2012

### RED BLOOD CELL AND PLATELET ANTIGENS

These red blood cell (RBC) and human platelet antigen (HPA) predictions are based on published genotype to phenotype correlations for the alleles present. Some antigens have also been serologically determined using traditional blood typing methods.

#### SUMMARY

**ABO Rh Blood Type: AB Negative.**

#### RBC Antigens

Antigen	Freq	Comments
AB	[4%]	No risk of alloantibody formation in individual. Very desirable platelet donor.
Yk(a-)	[8%]	Risk of alloantibody formation in individual, but anti-Yk(a) is a clinically insignificant antibody.
D-	[15%]	Risk of alloantibody formation in individual. Desirable antigen negative platelet and RBC donor.
Jk(b-)	[26%]	Risk of alloantibody formation in individual. Desirable antigen negative RBC donor.
E-	[29%]	Risk of alloantibody formation in individual. Desirable antigen negative RBC donor.
C-	[32%]	Risk of alloantibody formation in individual. Desirable antigen negative RBC donor.

#### Platelet Antigens

Antigen	Freq	Comments
HPA-1(b-)	[73%]	Risk of platelet alloantibody formation in individual. Desirable antigen negative platelet donor for the third most common anti-platelet antigen alloantibody cause of platelet refractoriness and a known cause of Neonatal Alloimmune Thrombocytopenia (FNAIT).

#### DISCUSSION

During pregnancy or transfusion alloantibodies to blood group antigens and platelet antigens can form against foreign RBCs that contain immunogenic blood group and platelet antigens that the recipient is missing. These alloantibodies can cause clinically important complications during future transfusions and pregnancy.

#### Blood Production Transfusion

This test identified that this individual is most likely to form the following common alloantibodies: anti-Jk(b), anti-C, anti-E, and anti-HPA-1(b). However, this individual does NOT have an increased risk of forming unusual RBC or platelet alloantibodies, since this test also revealed a normal absence of low frequency antigens, normal presence of high frequency antigens, and no antigen gene rearrangements.

#### Blood Production Donation

**This person is a very desirable universally compatible platelet donor** since AB Negative individuals, which make up less than 1% of the population, do not have naturally occurring anti-A and anti-B RBC alloantibodies and their RBCs are missing the D antigen so the small fraction of retained RBCs will not induce anti-D alloantibody formation. This person is also a desirable RBC donor missing the RBC antigens D, Jk(b), C, and E, which are common anti-RBC alloantibody targets. Given the population distribution of the C and E antigens, the combination of a donor being C- and E- is very desirable, since many individuals will form both anti-C and anti-E RBC alloantibodies. They are also a desirable platelet donor missing the platelet antigen HPA-1(b), which is the third most common anti-platelet antigen alloantibody cause of platelet refractoriness and a known cause of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). If interested in becoming a platelet and/or RBC donor, this individual is encouraged to contact the BWH donor recruitment supervisor (Malissa Lichtenwalter 617-632-3206, MLichtenwalter@partners.org) and mention that our testing found them to be ABO Rh Blood Type AB Negative; RBC antigen Jk(b-), E-, and C-; and platelet antigen HPA-1(b-).

### GENERAL GENOME REPORT(CONTINUED)

#### RED BLOOD CELL ANTIGENS

D	C	c	E	e	K	k	Fy(a)	Fy(b)	Jk(a)	Jk(b)	M	N	S	s
-	-	+	-	+	-	+	+	+	+	-	+	+	-	+

Lu(a)	Lu(b)	Au(a)	Au(b)	Kp(a)	Kp(b)	Kp(c)	Di(a)	Di(b)	Wr(a)	Wr(b)	Yt(a)	Yt(b)	Sc1	Sc2
[-]	[+]	[+]	[-]	[-]	[+]	[-]	[-]	[+]	[-]	[+]	[+]	[-]	[+]	[-]

Do(a)	Do(b)	Jo(a)	Hy	Co(a)	Co(b)	LW(a)	LW(b)	Cr(a)	Kn(a)	Kn(b)	Sl(a)	Vil	Yk(a)	KCAM
[-]	[+]	[+]	[+]	[+]	[-]	[+]	[-]	[+]	[+]	[-]	[+]	[-]	[-]	[+]

McC(a)	McC(b)	In(a)	In(b)	Ok(a)	MER2	JMHK	JMHL	FORS	A	B	H
[+]	[-]	[-]	[+]	[+]	[+]	[+]	[+]	[-]	+	+	+

#### PLATELET ANTIGENS

1a	1b	2a	2b	3a	3b	4a	4b	5a	5b	6bw	7bw	8bw	9bw
[+]	[-]	[+]	[-]	[+]	[+]	[+]	[-]	[+]	[+]	[-]	[-]	[-]	[-]

10bw	11bw	12bw	13bw	14bw	15a	15b	16bw	17bw	18bw	19bw	20bw	21bw	22bw
[-]	[-]	[-]	[-]	[-]	[+]	[+]	[-]	[-]	[-]	[-]	[-]	[-]	[-]

23bw	24bw	25bw	26bw	27bw
[-]	[-]	[-]	[-]	[-]

Key: [+] presence of antigen predicted by genotyping; + presence of antigen predicted by genotyping and confirmed by serology; +\* presence of antigen detected by serology, genotype prediction not available; [+w] weak presence of antigen predicted by genotyping; +w weak presence of antigen predicted by genotyping and confirmed by serology; +w\* weak presence of antigen detected by serology, genotype prediction not available; [-] absence of antigen predicted by genotyping; - absence of antigen predicted by genotyping and confirmed by serology, -\* absence of antigen detected by serology, genotype prediction not available; NC indicates no sequencing coverage, Dis indicates discordant. Rare (less than 5% population frequency) presence or absence of antigen is indicated in red.

## METHODOLOGY

Genomic sequencing is performed using next generation sequencing on the Illumina HiSeq platform. Genomes are sequenced to at least 30X mean coverage and a minimum of 95% of bases are sequenced to at least 8X coverage. Paired-end 100bp reads are aligned to the NCBI reference sequence (GRCh37) using the Burrows-Wheeler Aligner (BWA), and variant calls are made using the Genomic Analysis Tool Kit (GATK). Variants are subsequently filtered to identify: (1) variants classified as disease causing in public databases; (2) nonsense, frameshift, and +/-1,2 splice-site variants that are novel or have a minor allele frequency <1% in European American or African American chromosomes from the NHLBI Exome Sequencing Project (<http://evs.gs.washington.edu/EVS/>); and (3) rs11212617 (C11orf65; metformin), rs12248560 (CYP2C19; clopidogrel), rs4244285 (CYP2C19; clopidogrel), rs4986893 (CYP2C19; clopidogrel), rs28399504 (CYP2C19; clopidogrel), rs41291556 (CYP2C19; clopidogrel), rs72552267 (CYP2C19; clopidogrel), rs72558186 (CYP2C19; clopidogrel), rs56337013 (CYP2C19; clopidogrel), rs1057910 (CYP2C9; warfarin), rs1799853 (CYP2C9; warfarin), rs7900194 (CYP2C9; warfarin), rs9332131 (CYP2C9; warfarin), rs28371685 (CYP2C9; warfarin), rs28371686 (CYP2C9; warfarin), rs9923231 (VKORC1; warfarin), rs4149056 (VKORC1; simvastatin), and rs1045642 (ABCB1; digoxin). The evidence for phenotype-causality is then evaluated for each variant resulting from the filtering strategies above and variants are classified according to LMM criteria (<http://pcpgm.partners.org/LMM>). Only those variants with evidence for causing highly penetrant disease or contributing to disease in a recessive manner are reported. Before reporting, all variants are confirmed via Sanger sequencing or another orthogonal technology. The initial sequencing component of this test was performed by the Illumina Clinical Services Laboratory (San Diego, CA CLIA# 05D1092911) and the alignment, variant calling, data filtering, Sanger confirmation and interpretation were performed by the Laboratory for Molecular Medicine at the Partners Healthcare Center for Personalized Genetic Medicine (Cambridge, MA CLIA#22D1005307). This test has not been cleared or approved U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.



## GENERAL GENOME REPORT(CONTINUED)

### LIMITATIONS

It should be noted that this test does not sequence all bases in a human genome and not all variants have been identified or interpreted. Triplet repeat expansions, translocations and large copy number events are currently not reliably detected by genome sequencing. Furthermore, not all disease-associated genes have been identified and the clinical significance of variation in many genes is not well understood. It is recommended that genomic sequencing data is periodically reinterpreted, especially when new symptoms arise.

### REFERENCES

- Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH. 2008. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. *Pharmacogenet. Genomics.* 18(4):299-305.
- Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR. 2012. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. *Pharmacogenomics J.* 12(3):233-7.
- Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ. 2008. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. *Blood.* 112(4):1022-7.
- Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, Barrett-Connor E, Knowler WC, Shuldiner AR, Pollin TI, Diabetes Prevention Program Research Group. 2012. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. *Diabetes Care.* 35(9):1864-7.
- Franco B, Meroni G, Parenti G, Levilliers J, Bernard L, Gebbia M, Cox L, Maroteaux P, Sheffield L, Rappold GA, Andria G, Petit C, Ballabio A. 1995. A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. *Cell.* 81(1):15-25.
- GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, Markus HS, Mathew CG, Plomin R, Rautanen A, Sawcer SJ, Samani NJ, Trembath R, Viswanathan AC, Wood NW, MAGIC investigators, Harries LW, Hattersley AT, Doney AS, Colhoun H, Morris AD, Sutherland C, Hardie DG, Peltonen L, McCarthy MI, Holman RR, Palmer CN, Donnelly P, Pearson ER. 2011. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. *Nat. Genet.* 43(2):117-20.
- Hamosh A, Trapnell BC, Zeitlin PL, Montrose-Rafizadeh C, Rosenstein BJ, Crystal RG, Cutting GR. 1991. Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. *J. Clin. Invest.* 88(6):1880-5.
- Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johné A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 97(7):3473-8.
- International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N. Engl. J. Med.* 360(8):753-64.
- Kerem BS, Zielenski J, Markiewicz D, Bozon D, Gazit E, Yahav J, Kennedy D, Riordan JR, Collins FS, Rommens JM. 1990. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. *Proc. Natl. Acad. Sci. U.S.A.* 87(21):8447-51.
- Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K. 2002. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. *Clin. Pharmacol. Ther.* 72(2):209-19.
- Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ, International Warfarin Pharmacogenetics Consortium. 2010. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. *Blood.* 115(18):3827-34.
- Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. 2000. Genetic modulation of oral anticoagulation with warfarin. *Thromb. Haemost.* 84(5):775-8.
- Matos-Miranda C, Nimmo G, Williams B, Tysoe C, Owens M, Bale S, Braverman N. 2013. A prospective study of brachytelephalangic chondrodysplasia punctata: identification of arylsulfatase E mutations, functional analysis of novel missense alleles, and determination of potential phenocopies. *Genet. Med.*
- Nino M, Matos-Miranda C, Maeda M, Chen L, Allanson J, Armour C, Greene C, Kamaluddeen M, Rita D, Medne L, Zackai E, Mansour S, Superti-Furga A, Lewanda A, Bober M, Rosenbaum K, Braverman N. 2008. Clinical and molecular analysis of arylsulfatase E in patients with brachytelephalangic chondrodysplasia punctata. *Am. J. Med. Genet. A.* 146A(8):997-1008.

**GENERAL GENOME REPORT(CONTINUED)**

- Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. *Pharmacogenet. Genomics.* 16(12):873-9.
- Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahé I, Legendre C, Taillandier-Hérèche E, Durand-Gasselín B, Houllier AM, Verrier P, Beaune P, Lorient MA, Siguret V. 2010. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. *Clin. Pharmacol. Ther.* 87(1):57-64.
- Raben N, Sherman J, Miller F, Mena H, Plotz P. 1993. A 5' splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). *J. Biol. Chem.* 268(7):4963-7.
- Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. 2010. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. *Pharmacogenomics.* 11(6):781-91.
- SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. 2008. SLCO1B1 variants and statin-induced myopathy--a genomewide study. *N. Engl. J. Med.* 359(8):789-99.
- Sheffield LJ, Osborn AH, Hutchison WM, Sillence DO, Forrest SM, White SJ, Dahl HH. 1998. Segregation of mutations in arylsulphatase E and correlation with the clinical presentation of chondrodysplasia punctata. *J. Med. Genet.* 35(12):1004-8.
- Shoshani T, Augarten A, Gazit E, Bashan N, Yahav Y, Rivlin Y, Tal A, Seret H, Yaar L, Kerem E. 1992. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. *Am. J. Hum. Genet.* 50(1):222-8.
- Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A. 2010. Cytochrome 2C19\*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation.* 121(4):512-8.
- Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. 2006. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clin. Pharmacol. Ther.* 79(1):103-13.
- Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P. 2009. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. *PLoS Genet.* 5(3):e1000433.
- Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schömig A, Kastrati A. 2010. Protective effect of the CYP2C19 \*17 polymorphism with increased activation of clopidogrel on cardiovascular events. *Am. Heart J.* 160(3):506-12.
- Verstuyft C, Morin S, Robert A, Lorient MA, Beaune P, Jaillon P, Becquemont L. 2001. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. *Pharmacogenetics.* 11(8):735-7.
- Vidaud M, Fanen P, Martin J, Ghanem N, Nicolas S, Goossens M. 1990. Three point mutations in the CFTR gene in French cystic fibrosis patients: identification by denaturing gradient gel electrophoresis. *Hum. Genet.* 85(4):446-9.

**Name:DOE, JONATHAN**

DOB: 12/34/5678

MRN: 123456789

Sex: Male

Specimen: Blood, Peripheral

Race: Caucasian

Received: 12/34/5678

**Accession ID: PMXX-67890**

Family #: F12345

Referring physician: MedSeq

Referring facility: MedSeq

**CARDIAC RISK REPORT****RESULT SUMMARY**

This Cardiac Risk Report returns genetic variants that may influence risk or treatment for cardiovascular disease. Analysis covers 102 genes for monogenic cardiac disease including cardiomyopathies, arrhythmias, aortopathies, congenital heart disease as well as vascular and valvular disorders. This report includes pathogenic variants found in these genes (also returned on the General Genome Report). In addition, variants of uncertain significance in these genes are returned in this report. Please note that the following genes had less than 95% coverage at a depth of 8X or higher: CTF1 (94%), HCN2 (89%), and PABPN1 (91%). Fasting lipid levels are predicted based on the presence or absence of multiple genetic variants and, finally, alleles conferring a small to moderate risk for cardiovascular disease are returned from analysis of 161 cardiovascular risk loci. All results are summarized on page 1 with further details provided on subsequent pages.

**MONOGENIC CARDIAC DISEASE RISK: 0 VARIANTS IDENTIFIED**

This test did NOT identify genetic variants known or expected to cause existing cardiovascular disease or the development of cardiovascular disease in this individual's lifetime.

**POSSIBLE MONOGENIC CARDIAC DISEASE RISK: 1 VARIANT IDENTIFIED**

This test identified 1 genetic variant of uncertain significance that could be responsible for existing cardiovascular disease or the development of cardiovascular disease in this individual's lifetime.

Disease (Inheritance)	Phenotype	Gene (Variant)	Classification
Brugada syndrome (Autosomal dominant)	Cardiac conduction abnormalities	CACNA1C (c.1468G>A p.Gly490Arg)	Uncertain significance

**POLYGENIC PREDICTED FASTING LIPID PROFILE**

The following lipid profile is predicted by known genetic factors, age, and gender and is not reflective of environmental, medication or other factors. These values are based on large epidemiologic studies and are not intended to substitute for measured values.

- LDL 116 mg/dL
- HDL 47 mg/dL
- Triglycerides 140 mg/dL

**ALLELES CONFERRING SMALL-MODERATE RISK MODIFICATION FOR EIGHT CARDIOVASCULAR PHENOTYPES**

Phenotype	Contextual Data		Patient Results			
	Population Prevalence of Phenotype for Age 54	Proportion of Variation in Phenotype Liability Explained by Common Genetic Variants	Number of Risk Loci Evaluated	Number of Total Risk Alleles Identified*	Polygenic Relative Risk**	Percentile Rank of Relative Risk**
Abdominal aortic aneurysm	6%	Unknown	3	3/6	1.0	40-50th
Atrial fibrillation	2%	10%	11	4/22	<0.6	0-10th
Coronary heart disease	6% (Age 40-59)	<10%	60	60/120	2.2	80-90th
Type 2 Diabetes	13% (Age 45-64)	5-10%	70	79/140	>3.6	90-100th
Hypertension	52%	<10%	3	2/6	1.0	40-50th
Obesity	37% (Age 40-59)	1-2%	7	12/14	1.2	60-70th
Platelet aggregation	Unknown	5-10%	4	0/8	<0.6	0-10th
QT prolongation	Unknown	7%	3	5/6	1.0	40-50th

\*# of total possible risk alleles = # risk loci x 2 alleles per loci.

\*\* As data utilized in this analysis were derived from non-longitudinal association studies, "Relative Risk from Common Genetic Variation" pertains to near-term risk of developing a phenotype (e.g. approximately 5 year risk), not lifetime risk. "Relative Risk from Common Genetic Variation" and "Percentile Rank of Relative Risk from Common Genetic Variation" values have been estimated using the 1000 Genomes European cohort.

## CARDIAC RISK REPORT (CONTINUED)

It should be noted that this clinical report is limited to only a subset of variants that have met criteria for inclusion. Not all variants identified have been analyzed and not all regions included in the genome have been adequately sequenced. The polygenic predicted values for lipid levels are based on large epidemiologic studies and may not apply to each individual patient (model from N. Stitzel and S. Sunyaev, personal communication). The summary risk assessments above, for small-moderate effect alleles, are based on combining individual risk allele data in ways that may not always apply to each individual patient. These results should be interpreted in the context of the patient's medical evaluation, family history, and racial/ethnic background.

## DETAILED VARIANT INFORMATION

### MONOGENIC VARIANTS CONFERRING HIGH RISK OF DISEASE

This test did NOT identify individual genetic variants known or expected to cause existing cardiovascular disease or the development of cardiovascular disease in this individual's lifetime.

### MONOGENIC VARIANTS POSSIBLY CONFERRING HIGH RISK OF DISEASE

Disease (Inheritance)	Gene (Transcript)	Variant (Classification)	Variant Frequency	Disease Prevalence	References
Brugada syndrome (Autosomal Dominant)	CACNA1C (NM_000719.6)	c.1468G>A p.Gly490Arg heterozygous (Uncertain significance)	5/4,020 European American	1-5/10,000	Antzelevitch 2007

**VARIANT INTERPRETATION:** The Gly490Arg variant in CACNA1C has been identified in a single patient with Brugada syndrome but was also identified in 5/4020 of European American chromosomes by the NHLBI Exome Sequencing Project (<http://evs.gs.washington.edu/EVS/>). Functional studies indicate this variant does not result in abnormal protein localization, but may lead to abnormal Ca<sup>2+</sup> current (Antzelevitch 2007). Additional information is needed to fully assess the clinical significance of the Gly490Arg variant.

**DISEASE INFORMATION:** Brugada syndrome is characterized by cardiac conduction abnormalities (ST-segment abnormalities in leads V1-V3 on ECG and a high risk for ventricular arrhythmias) that can result in sudden death. Other conduction defects can include first-degree AV block, intraventricular conduction delay, right bundle branch block, and sick sinus syndrome. Adapted from GeneReviews abstract: <http://www.ncbi.nlm.nih.gov/books/NBK1517/>

**FAMILIAL RISK:** Brugada syndrome is inherited in an autosomal dominant manner. Most individuals diagnosed with Brugada syndrome have an affected parent. The proportion of cases caused by a de novo mutation is estimated at 1%. Each child of an individual with Brugada syndrome has a 50% chance of inheriting the mutation. Other biologically related family members may also have this variant.

## METHODOLOGY

Genomic sequencing is performed using next generation sequencing on the Illumina HiSeq platform. Genomes are sequenced to at least 30X mean coverage and a minimum of 95% of bases are sequenced to at least 8X coverage. Paired-end 100bp reads are aligned to the NCBI reference sequence (GRCh37) using the Burrows-Wheeler Aligner (BWA), and variant calls are made using the Genomic Analysis Tool Kit. All variants in 103 monogenic cardiac disease genes are evaluated and classified according to pathogenicity. Pathogenic, likely pathogenic and variants of uncertain significance with higher suspicion for disease-causality are reported. In addition, risk alleles identified at 163 loci involved in cardiac disease are also reported. Odds ratios are combined to provide overall assessment of risk for broad phenotypes. It should be noted that this test does not sequence all bases in a human genome and will not detect or interpret all variants in a genome. Furthermore, the clinical significance of many variants is not well understood. The technical component of this test as developed and its performance characteristics determined by the Illumina CLIA Lab (San Diego, CA CLIA# 05D1092911) and the interpretive algorithms and clinical reports were generated by the Laboratory for Molecular Medicine at the Partners Healthcare Center for Personalized Genetic Medicine (LMM, 65 Landsdowne St, Cambridge, MA 02139; 617-768-8500; CLIA#22D1005307). This test has not been cleared or approved by the U.S Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.

## LIMITATIONS

It should be noted that this test does not sequence all bases in a human genome and not all variants have been identified or interpreted.

## CARDIAC RISK REPORT (CONTINUED)

Furthermore, not all cardiac disease-associated genes have been identified and the clinical significance of variation in many genes is not well understood. Therefore, it is recommended that genomic sequencing data is periodically reinterpreted, especially when new symptoms arise. It should be noted that the polygenic predicted values for lipid levels are based on large epidemiologic studies and may not apply to each individual patient (model from N. Stitzel and S. Sunyaev, personal communication). The summary risk assessments above, for small-moderate effect alleles, are based on combining individual risk allele data in ways that may not always apply to each individual patient.

## REFERENCES

Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP, Burashnikov E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haïssaguerre M, Schimpf R, Borggrefe M, Wolpert C. 2007. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. *Circulation*. 115(4):442-9.